An observational, prospective, single-center study evaluating safety and efficacy of pharmacological cardioversion of Flecainide, Ibutilide, Vernakalant and Amiodarone in patients with recent-onset atrial fibrillation.

Trial Profile

An observational, prospective, single-center study evaluating safety and efficacy of pharmacological cardioversion of Flecainide, Ibutilide, Vernakalant and Amiodarone in patients with recent-onset atrial fibrillation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Amiodarone (Primary) ; Flecainide (Primary) ; Ibutilide (Primary) ; Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jun 2016 New trial record
    • 11 May 2016 Endpoint has not been met (Successful pharmacological conversion of recent-onset atrial fibrillation (AF) to restoring sinus rhythm), as per an article published in the American Journal of Emergency Medicine
    • 11 May 2016 Results published in the American Journal of Emergency Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top